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Expanded Disability status scale 
A B S T R A C T   
Background: Fingolimod lowers the number of relapses in multiple sclerosis (MS) patients and slows down disease 
progression, but causes a broad spectrum of side effects. Our aim was to estimate the benefit-harm balance of 
fingolimod using individual patient data from FREEDOMS, a randomized controlled trial that compared two 
different dosages of fingolimod to placebo. 
Methods: We modelled the health status of patients over two years on a scale ranging from 0 (worst health or 
death) to 100 (maximum health). The model considered Expanded Disability Status Scale measurements, re-
lapses and adverse events. We compared the mean health status between arms, and the proportion of trial 
participants for whom health declined or improved compared to baseline by a predefined minimal important 
difference of 4.6 or more. 
Results: The main analysis showed a net benefit for fingolimod 0.5mg compared to placebo, with an average 
health status difference over two years of 2.7 (95% CI 2.2 to 3.2). Patients on fingolimod 0.5mg were 0.53 (95% 
CI 0.40-0.72, p<0.001) times less likely to have a relevant decline in health status compared to patients on 
placebo, corresponding to a number needed to treat of 8 to prevent one relevant decline in health status. All 
sensitivity analyses favoured fingolimod 0.5mg. 
Conclusion: Although fingolimod’s net benefit did not reach the clinical relevance on average, the decreased risk 
for a decline in health over two years may be relevant. This approach could be applied to other MS drugs and 
provide an objective evidence base for guideline recommendations.   
1. Introduction 
Fingolimod is an oral drug approved at the dosage of 0.5mg once 
daily for treating patients affected by relapsing remitting multiple 
sclerosis (RRMS), the most common form of multiple sclerosis (MS) 
(Goldenberg, 2012). A systematic review of randomized controlled trials 
(RCTs) found that fingolimod 0.5mg lowered the risk of relapses 
compared to placebo and interferon beta 1a (La Mantia et al., 2016). 
However, RCTs and post marketing surveillance reported adverse events 
(AEs) that raised concerns about the safety of fingolimod. The uncer-
tainty around the benefit-harm balance led to different indications for 
fingolimod across health care systems. The NICE institute (NICE, 2012), 
for instance, recommends fingolimod only for highly active RRMS, while 
the FDA approved its usage in a broader range of MS forms (FDA, 2019). 
Systematic reviews and health technology assessments usually 
consider benefits and harms separately and rarely use a systematic, 
quantitative approach to combine all relevant outcomes in order to 
judge the benefit-harm balance (Puhan et al., 2013). If many benefit and 
harm outcomes are patient-important, it is challenging to judge the 
balance of benefits and harms without a systematic approach. In the 
absence of systematic, quantitative assessments, regulatory decisions 
and guideline recommendations can be discrepant (Yu et al., 2014; 
Yebyo et al., 2019). 
Instead, quantitative modelling can help clarify the benefit-harm 
balance of a treatment. Therefore, to clarify the benefit-harm balance 
of fingolimod, we performed a modelling study based on individual 
patient data (IPD) from FREEDOMS (FTY720 Research Evaluating Ef-
fects of Daily Oral Therapy in Multiple Sclerosis) (Kappos et al., 2010). 
This RCT compared daily doses of 0.5mg vs 1.25mg of fingolimod vs 
placebo in patients affected by RRMS. Analysing IPD has numerous 
advantages compared to aggregate data: it allows for incorporating 
follow-up assessments, relapses and adverse events as well as the 
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sequence and co-occurrence of these events within individual patients. 
2. Methods 
2.1. Study design 
We performed a quantitative benefit-harm modelling study based on 
IPD of the phase 3 trial FREEDOMS. Briefly, we first estimated the health 
status of each participant over the 24-months study period based on the 
Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) score at base-
line and at scheduled visits and additionally considered all relapses and 
AEs. We then compared the health status between participants of the 
three trial arms. 
FREEDOMS compared two different dosages of fingolimod, 1.25mg 
or 0.5mg once daily (later referred to as fingolimod 1.25mg and fingo-
limod 0.5mg) to matching placebo. The trial population consisted of 
patients with RRMS who were between 18 to 55 years of age, had a 
baseline EDSS score between 0 to 5.5, and experienced at least one 
relapse in the year before enrolment, or two or more relapses in the two 
years before enrolment. Patients were eligible if they had prior treat-
ment with interferons, glatiramer acetate and natalizumab (see Sup-
plemental Data, Section 3) but with a washout period of at least three 
months before randomization. 
We were granted access to IPD of FREEDOMS through the Clinical 
Study Data Request platform (CSDR, ClinicalStudyDataRequest.com) 
that offers access to trials released by a consortium of sponsors. Our 
application was approved by the platform Independent Research Board 
and a data sharing agreement (1933) was signed by the study sponsor 
Novartis and us. The sponsor of the trial had no influence on the study 
question, the methods, the analysis and the interpretation of the results, 
writing of the manuscript or the decision to publish. 
2.2. Estimating the health status for individuals based on EDSS, relapses 
and adverse events 
We modelled the health status of each individual in the trial on a 
scale from 100 (perfect health) to 0 (death, as assumed to represent 
worst health status), as commonly used in health economic analyses or 
burden of disease studies (Department of Information E and R, WHO G, 
2017). In a first step, we estimated the health status based on the EDSS at 
baseline and at scheduled visits (see Supplemental Data, Fig. S4). In a 
second step, we reduced the health status if the individual experienced 
relapses or AEs. 
We accounted for relapse severity (mild, moderate, severe, (Naldi 
et al., 2011; Ahmad and Taylor B, 2017) Supplemental Data, section 
1.2.1) and duration, including whether patients were hospitalized 
and/or treated with systemic corticosteroids. We considered only re-
lapses confirmed by the EDSS, but we had to attribute them a drop in 
health status based on the reported severity since EDSS scores measured 
for relapse assessments were not available in the dataset. Relapses were 
classified as mild, moderate, severe, very severe; if a relapse was coded 
as mild, the EDSS rise compared to the stable status was estimated at 1.7 
(the central value for the range, see Table 1) and the corresponding 
health status drop was 9.1, assuming no treatment. The population 
under study did not experience very severe relapses. We considered all 
AEs, which were coded using preferred terms of the Medical Dictionary 
for Regulatory Activities (MedDRA). We also considered their severity 
(no symptoms, mild, moderate, severe), duration and therapeutic ac-
tions taken to treat them, which were all reported in the datasets. 
“Multiple sclerosis relapse” and “Multiple Sclerosis” AEs were excluded 
to avoid double counting of relapses. We decided to not incorporate 
Multiple Sclerosis Functional Composite (MSFC) assessments in our 
analysis, since they could lead to double counting of the functional 
status. Furthermore, we designed a method applicable to different 
studies and with the MSFC we would face a challenge for applicability of 
the methods. 
2.3. Drops in health status due to relapses and adverse events 
We decided a priori how much the health status dropped due to a 
relapse or an AE of a specific severity. We applied the same drops to all 
patients irrespective of group assignment. The health status of patients 
dropped the first day of a relapse or AE and then gradually recovered 
from the second day of the event (Supplemental Data, section 1.2.1 and 
1.2.2). Preference surveys that elicit the importance of each specific 
event would be ideal to empirically determine the drop in health status 
(Aschmann et al.; Aschmann et al., 2019; Yebyo et al., 2018; Zhang 
et al., 2019), but we could not identify any such studies that covered the 
broad spectrum of AEs recorded in FREEDOMS. Instead, Table 1 and 
Table 2 show how we defined a drop in health status for each relapse and 
AE respectively. 
Table 1 shows relapse drops used in the main analysis. 
Table 2 shows Adverse Event categorisations and drops. 
Drops increased with severity and depending on the action taken 
(details on how the drops were defined are in the Supplemental Data). 
The duration of an AE did not impact on the initial drop at day 1. AEs 
were coded in FREEDOMS as no symptoms, mild, moderate and severe, 
and we additionally defined four categories according to clinical 
judgement of how much impact an AE is likely to have (see AE Drops, 
Table 6, Supplemental Data). 
To assign the drops we combined an algorithm with a manual change 
of single AE drop, when necessary. During this step it is possible that we 
created some discrepancies in drop assignment. However, this had no 
impact in our results, since AEs are coded equally in all arms and 
sensitivity analyses where we changed AEs drops showed not significant 
difference in comparison to the main findings (see sensitivity analyses 
for AEs). This process allowed us to account for different severities of the 
preferred terms within the same superior term (see AE Drops, Table 6, 
Supplemental Data, for superior and preferred term classification and 
drops). 
We accounted in the model that more AEs could happen at the same 
time (Slankamenac et al., 2013). We performed a number of sensitivity 
analyses to assess how sensitive the benefit-harm balance of fingolimod 
was to our defined drops in health status (see Supplemental Data, 
Table 4 and Table 5). In two sensitivity analyses, we assigned larger or 
smaller drops to relapses compared to the main analysis. We assumed 
Table 1 
Drops in health status for relapses.  




Relapse Mild None 1.7 9.1   
Systemic 
corticosteroids 
- 9.6   
Hospitalization - 22.0   
SCd + hospitalization - 22.2  
Moderate None 2.7 15.8   
Systemic 
corticosteroids 
- 16.1   
Hospitalization - 25.5   
SC + hospitalization - 25.7  
Severe None 3.5 21.9   
Systemic 
corticosteroids 
- 22.1   
Hospitalization - 29.7   
SC + hospitalization - 29.8  
a Three categories based on Expanded Disability Status Scale; 
b Four categories, the latter being the combination of the previous two. 
(Further details on Action taken combination are provided in the Supplemental 
Data); 
c It shows the EDSS rise, corresponding to the health status drop compared to 
the stable status. EDSS scores are set according to relapse severity; the score was 
determined considering the central value for severity range of values (mild (0-2), 
moderate (2.5 -3), severe (>3))(11); 
d Systemic corticosteroids. 
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extreme drops for both sensitivity analyses in order to generate a range 
in which the difference in health status between groups most likely falls. 
We left all other model parameters constant for these sensitivity 
analyses. 
Following the same logic, we conducted two sensitivity analyses to 
test how different drops for adverse events impacted on the results. In 
one sensitivity analysis, the drops increased less with severity than in the 
main analysis. In another sensitivity analysis, we did not consider mild 
AEs in order to explore the extent to which moderate and severe events 
alone impacted the benefit-harm balance of fingolimod. 
Finally, we performed a sensitivity analysis with different assump-
tions to convert EDSS scores to a health status scale. 
2.4. Censoring 
In FREEDOMS, at two years, approximately 20% of patients with 
fingolimod 1.25mg and with placebo, and 10% of patients with fingo-
limod 0.5mg were censored. We used multiple imputation (25 imputed 
data sets) with “predictive mean matching” (package mice (Gaffert and 
Meinfelder, 2016)) to account for censoring. 
2.5. Statistical analysis 
We predefined a minimal important difference (MID) to judge the 
clinical relevance of the difference in health status between trial arms. 
We computed the MID as half the standard deviation of the health status 
at baseline (Norman et al., 2003), which equalled 4.6. A systematic re-
view found that distribution-based approaches yielded more conserva-
tive, but similar values for the MID compared to anchor-based 
approaches (Jayadevappa et al., 2017). We did not find any survey 
which included all our outcomes, however in a study using anchor-based 
approach the MID was set at 1 for the EDSS range of 0-5.5 (Costelloe 
et al., 2007), which is identical to the range of baseline EDSS in FREE-
DOMS. Taking into account the non-linearity of the conversion from 
EDSS to the health status scale, this corresponds to a MID of about 8 on 
the health status scale, which is larger than the distribution-based MID 
of 4.6. We preferred to use the distribution-based method, which is 
calculated directly on our sample; in addition, our main conclusions 
would not change using a MID of 8. 
We calculated the difference of the mean health status between the 
groups. We defined that if the 95% confidence interval of this difference 
did not cross +4.6 or -4.6, the average health gain or loss would not be 
clinically relevant. Furthermore, we determined the proportion of pa-
tients who had a relevant improvement or decline (by 4.6 or more) 
compared to baseline after two years. We calculated the risk ratio be-
tween treatment groups for a relevant improvement or decline, respec-
tively, and the number needed to treat. 
All analyses were performed using R version 3.4.3 on the CTDR 
platform. 
2.6. Data availability 
The data that support the findings of this study are publicly available 
on the CSDR platform at request from the study sponsor Novartis. 
3. Results 
3.1. Main analysis 
Fig. 1 shows the average health status in the three treatment groups 
over two years. The health status at baseline was around 85 for all three 
groups, which is, as expected, lower than the health status of a general 
population of similar age (which has an average health of 89 at age 35- 
45 (Fryback et al., 2007)). 
Patients on fingolimod 0.5mg had the best health status over the 
entire study period. There were few relapses over the entire study period 
and after the first quarter of the year, adverse events were not infrequent 
but mostly of low to moderate severity. As a consequence, health status 
was stable across the two years of the trial. 
In contrast we observed that the health status of patients in placebo 
Table 2 
Drops in health status for adverse events.  
Severity of symptoms Therapeutic action taken according to database Category of adverse events according to potential impact on health status   
Very small impact Small impact Moderate impact Large impact 
No symptoms None 1.9 2.5 3.7 5.0  
Study drug dose adjusted 2.1 2.7 3.9 5.1  
Minimal therapy given 3.5 3.9 4.8 5.8  
Moderate therapy given 8.2 8.4 8.8 9.4  
Study drug dose suspended 20.1 20.2 20.3 20.6  
(Prolonged) hospitalization 48.0 48.1 48.2 48.3 
Mild symptoms None 3.8 5.0 7.5 10.0  
Study drug dose adjusted 3.9 5.1 7.6 10.1  
Minimal therapy given 4.8 5.8 8.1 10.4  
Moderate therapy given 8.8 9.4 11.0 12.8  
Study drug dose suspended 20.3 20.6 21.4 22.4  
(Prolonged) hospitalization 48.1 48.2 48.6 49.0 
Moderate symptoms None 7.5 10.0 15.0 20.0  
Study drug dose adjusted 7.6 10.1 15.0 20.0  
Minimal therapy given 8.1 10.4 15.3 20.2  
Moderate therapy given 11.0 12.8 17.0 21.5  
Study drug dose suspended 21.4 22.4 25.0 28.3  
(Prolonged) hospitalization 48.6 49.0 50.3 52.0 
Severe symptoms None 15.0 20.0 30.0 40.0  
Study drug dose adjusted 15.0 20.0 30.0 40.0  
Minimal therapy given 15.3 20.2 30.2 40.1  
Moderate therapy given 17.0 21.5 31.0 40.8  
Study drug dose suspended 25.0 28.3 36.1 44.7  
(Prolonged) hospitalization 50.3 52.0 56.6 62.5 
This table lists the drops in health status for one adverse event and its severity and therapeutic consequence. Drops for combinations of adverse event are explained in 
the Supplemental Data. 
1Adverse events (preferred MedDRA terms) were separated into 4 categories based on clinical judgement about the impact the adverse event is likely to have on health 
status when mild and no action is taken. For example, nausea was classified as an adverse event with very small impact, bradycardia as an adverse event with small 
impact, viral bronchitis as an adverse event with moderate impact, and macular oedema as an adverse event with large impact on health status. 
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and fingolimod 1.25mg arms deteriorated within the first month, 
although in a different way. As an explanation for these deteriorations, 
Fig. 1 shows the number of relapses and adverse events for each quarter 
year. Patients with placebo had almost twice the number of relapses 
compared to patients with fingolimod 0.5mg or 1.25mg in the first three 
months, and also substantially more relapses during the rest of the two 
Fig. 1. Mean health status of patients with fingolimod 0.5mg, fingolimod 1.25mg and placebo over two years. 
The figure shows the mean and 95% confidence interval of the mean health status in each group. 
Panel A represents a full health status scale (0 to 100); Panel B shows a partial health status scale (y axis, from 77 to 90) and health status curves for the three 
treatment groups; below two tables show the total relapse numbers during the corresponding time periods, covering 91 days each (x axis) and the total adverse event 
numbers during the same corresponding time periods. 
Fig. 2. Difference in mean health status between patients with fingolimod 0.5mg and placebo in the FREEDOMS trial. 
If the difference is positive, patients on fingolimod had a better health status on average than those on placebo. 
± 4.6 = Minimal Important Difference (MID). 
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years. As the study time progressed, we observed that these patients 
experienced a decreasing number of relapses over time. We observed a 
similar effect in the other two arms. 
Patients included in the trial consisted of both naive and previously 
treated patients, with a washout period of three months prior to 
randomization. For the placebo group we found that among those with 
no relapses in the first three months, 36% of patients were previously 
treated, with one relapse 45% and with two or more relapses 80% were 
previously treated, respectively. In the fingolimod 0.5mg group, the 
corresponding proportions were 57%, 51% and no one with two or more 
relapses (see Supplemental Data, Section 3). 
Throughout the two years, patients with placebo experienced more 
relapses than patients with fingolimod, which explains the constant 
decline of the health status. Health status of patients with fingolimod 
1.25mg also deteriorated in the first 92 days of the trial, but this is likely 
due to the frequent and often severe adverse effects. 
3.2. Difference in health status between fingolimod 0.5mg and placebo 
Fig. 2 shows the difference in mean health status between patients on 
fingolimod 0.5mg and on placebo. The mean difference across two years 
was + 2.7 (95% CI 2.2 to 3.2). Thus the difference did not reach the MID 
of 4.6 points but was close to the MID in the last months of the trial (for 
results of fingolimod 1.25mg vs placebo, see Supplemental Data). At two 
years, the difference was 3.8 (95% CI 2.1 to 5.6). 
We found that 27.0% (90/333) in the placebo group and 14.6% (54/ 
369) in the fingolimod 0.5 mg experienced a relevant decline in health 
status (i.e. MID of 4.6 points) over two years compared to baseline. This 
corresponds to a risk ratio of 0.54 (95% CI 0.40-0.73) and a number 
needed to treat to prevent one relevant decline in health status of 8. 
9.0% (30/333) in the placebo and 13.0 % (48/369) in the fingolimod 
0.5mg group experienced a relevant improvement in health status over 
two years (risk ratio of 1.45, 95% CI 0.98-2.22, p=0.12), corresponding 
to a number needed to treat of 25. Where not specified otherwise, p 
values for previously mentioned CI were < 0.01 
3.3. Sensitivity analyses with large and small drops for relapses 
Different drops for relapses showed very similar results to those of 
the main analysis (Fig. 3). In the sensitivity analysis where we assigned a 
smaller drop to relapses in comparison to the main analysis (Fig. 3, 
Relapse small drops), the benefit-harm balance still favoured fingolimod 
0.5mg, even though the difference over the entire study period (2.5, 
95% CI 1.8 to 3.3) and towards the end of the trial (3.5 95% CI 1.9 to 
5.1) was smaller. The Sensitivity Analysis with larger drops on relapses 
(Fig. 3, Relapse large drops) showed an average difference in health status 
over two years of 3.6 (95% CI 2.6 to 4.6), thus clinical relevance cannot 
be rejected with statistical significance in this sensitivity analysis with 
extreme weight on relapses. This result represents the most favourable 
benefit-harm balance fingolimod 0.5mg obtained across all analyses. 
The sensitivity analyses demonstrated that the benefit-harm balance of 
fingolimod 0.5mg is only moderately sensitive to how relapses and 
adverse events are weighted. 
3.4. Sensitivity analyses with different drops for Adverse Events 
In a sensitivity analysis in which we assigned drops for AEs that 
increased less with severity (Fig. 3, Adverse events small drops), and a 
sensitivity in which we did not take into account mild AEs (Fig. 3, 
Adverse events excl. mild), respectively, there were no relevant differ-
ences compared to the main results (2.7, 95% CI 2.0 to 3.5, and 2.7, 95% 
CI 1.9 to 3.4 over two years, respectively). When we considered the 
proportion of patients exceeding the MID, the treatment was superior 
over the entire study duration (RR 1.4, 95% CI 1.0 to 2.0, p = 0.05). 
3.5. Sensitivity analysis with different conversion of EDSS to health status 
scale 
With different assumptions to convert EDSS scores to health status 
(Twork et al., 2010) (Fig. 3, Modified EDSS conversion) and setting at 9 
the worse possible value/death (Orme et al., 2007), the average differ-
ence in health status over two years was 3.4 (95% CI 2.4 to 4.3). This 
should be considered as an extreme variation of how EDSS scores can be 
converted to a health status scale, however results are in agreement with 
the main analysis. 
P values are <0.01 in all sensitivity analyses. 
4. Discussion 
To our knowledge, a benefit-harm balance modelling study for fin-
golimod 0.5mg based on IPD from FREEDOMS was not been performed 
before. Our results showed that the benefit-harm balance favoured fin-
golimod 0.5mg over placebo with a difference that is statistically sig-
nificant, with a number needed to treat of fingolimod 0.5mg to prevent 
one relevant decline in health status over two years of 8. All sensitivity 
analyses showed similar results favouring fingolimod 0.5mg irrespective 
of how the drops in health status due to relapses and adverse events were 
defined. 
4.1. Clinical importance 
Our findings imply that the benefits of fingolimod 0.5mg, i.e. 
Fig. 3. Sensitivity analyses summary. 
The main analysis and all sensitivity analyses are shown. The error band represents the 95% CI of main analysis difference. 
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reducing the relapse rate, outweigh the AEs, and that fingolimod 0.5mg 
stabilizes the patients’ health status over time. Side effects were more 
frequent at the beginning of the study and decreased over time. The 
mean difference between the fingolimod 0.5mg and placebo groups was 
below the MID over the course of two years but almost reached the MID 
at the end of the study period. Interpreting the mean difference between 
groups with respect to the MID is conservative and may underestimate 
the net benefit of treatments. Therefore, we also determined the pro-
portion of patients with a relevant decline in health status over two years 
in order to calculate the risk reduction of such a decline with fingolimod 
0.5mg. The number needed to treat of fingolimod 0.5mg to prevent one 
relevant decline in health status over two years was 8 and indicates an 
absolute benefit. Whether this benefit is acceptable on a societal level 
depends on the cost effectiveness and cost impact associated with it, 
along with the context and resources of a particular country. 
Concerning AEs, qualitative recommendations for monitoring pa-
tients on fingolimod 0.5mg treatment, particularly for cardiovascular 
events, infections and macular oedema (Oh and O’Connor, 2013), were 
issued as well as measures to minimize the risk of rare brain infections 
(FDA, 2019; Anton et al., 2017; European Medicines Agency 2013; FDA, 
2012; Gilenya, 2012). Safety recommendations were based on case re-
ports, AEs collected in RCTs and signals from post marketing surveil-
lance. Our findings suggested that the safety profile of fingolimod 0.5mg 
is clearly better than fingolimod 1.25mg (a dosage that was not 
approved). Comparing fingolimod 0.5mg with placebo, the small num-
ber of severe cardiovascular events and infections had little impact on 
the benefit-harm balance. Progressive multifocal leukoencephalopathy 
(PML), a severe adverse event observed with many other 
disease-modifying MS drugs and associated with fingolimod 0.5mg 
intake (FDA), was never observed during FREEDOMS. 
4.2. Preference sensitivity of benefit-harm balance 
Our sensitivity analyses demonstrated that the model’s results are 
stable, even with extreme assumptions for how much relapses decrease 
the health status. Since these extreme assumptions did not change the 
results meaningfully, it is unlikely that additional empirical evidence on 
average patient preferences would change the estimated benefit-harm 
balance of fingolimod 0.5mg on a population level. However, patient 
preferences can vary (Yebyo et al., 2019; Aschmann et al.; Yu et al., 
2015). Preferences could differ across patients depending on the course 
of MS, sex, age and other factors, and the individual benefit-harm bal-
ance may depend on the individual’s preferences. For example, it is 
likely that not all patients would consider a number needed to treat of 8 
to avoid a decline of 4.6 or more over two years as clinically relevant. 
This underscores the importance for informed and shared decision 
making since the overall results from RCTs and analyses such as ours do 
not generalize to individual patients and their preferences. 
4.3. Strengths of the study 
We modelled the benefit-harm balance of fingolimod 0.5mg based on 
IPD, which allowed considering all relapses and AE events and their 
sequence over time. We performed several sensitivity analyses, which 
showed that the benefit-harm balance is stable and variations in average 
preferences had little to no impact. In addition, we observed a high 
number of relapses early in the study in the placebo arm, that was fol-
lowed by a decreasing relapse rate both of which were not described 
when FREEDOMS was published. This effect was smaller in fingolimod 
0.5mg arm, which reached the peak efficacy over time. 
4.4. Weaknesses of the study 
The duration of FREEDOMS was likely too short to identify rare AEs 
such as PML. We do not know how the benefit-harm balance of fingo-
limod 0.5mg looks like beyond 2 years of treatment. Due to the relatively 
small sample size of the trial, we could not perform subgroup analyses, 
and therefore we do not know if some groups may benefit more or less 
from fingolimod 0.5mg. We observed a greater number of AEs at the 
beginning than in the second year of the study, even in the placebo 
group. The strong decrease in AEs over time in all arms could be a 
consequence of a tolerance effect, and over-reporting at the beginning or 
under-reporting later on in the study. 
5. Conclusion 
Our results showed that the benefit-harm balance favoured fingoli-
mod 0.5 mg over placebo in a statistically significant manner. Fingoli-
mod ’s preventive effect reducing the risk of a decline in health status is 
likely to be clinically meaningful on a population level, despite the fact 
that the difference in health status did not reach the MID on average. 
This effect could, however, vary according to individual preferences 
depending on how a patient perceives the importance of relapses and 
adverse events, potentially changing the benefit-harm balance across 
patients. 
Our benefit-harm balance modelling study could pave the way for 
similar analyses of other MS drugs where the benefit-harm balance is 
debated and, thereby, provide an important and objective evidence base 
for guideline recommendations. 
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